Columbia Wanger Asset Management is Buying Celldex Therapeutics Inc. (NASDAQ:CLDX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Celldex Therapeutics Inc. (NASDAQ:CLDX) reported that Columbia Wanger Asset Management Llc. has picked up 6,195,855 of common stock as of 2017-02-10.
The acquisition brings the aggregate amount owned by Columbia Wanger Asset Management Llc. to a total of 6,195,855 representing a 5.1% stake in the company.
For those not familiar with the company, Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company’s pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.
A glance at Celldex Therapeutics Inc. (NASDAQ:CLDX)’s key stats reveals a current market capitalization of 416.17 million based on 122.28 million shares outstanding and a price at last close of $3.45 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-08-25, Ellberger picked up 5,000 at a purchase price of $14.00. This brings their total holding to 53,500 as of the date of the filing.
On the sell side, the most recent transaction saw Catlin unload 25,000 shares at a sale price of $18.00. This brings their total holding to 35,109.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Celldex Therapeutics Inc. (NASDAQ:CLDX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Natera Inc. (NASDAQ:NTRA) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Natera Inc. (NASDAQ:NTRA) reported that Claremont Creek Ventures L P. has picked up 7,020,856 of common stock as of 2017-02-09.
The acquisition brings the aggregate amount owned by Claremont Creek Ventures L P. to a total of 7,020,856 representing a 13.4% stake in the company.
For those not familiar with the company, Natera, Inc. is a diagnostics company. The Company’s product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening (Horizon) to determine carrier status for various severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening (PGS) and Spectrum Pre-implantation Genetic Diagnosis (PGD) to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization (IVF) cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother’s blood and a blood sample from the alleged father(s).
A glance at Natera Inc. (NASDAQ:NTRA)’s key stats reveals a current market capitalization of 490.34 million based on 52.38 million shares outstanding and a price at last close of $9.31 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-06-19, Steuart picked up 66,621 at a purchase price of $11.94. This brings their total holding to 83,752 as of the date of the filing.
On the sell side, the most recent transaction saw Rosenman unload 1,850 shares at a sale price of $8.95. This brings their total holding to 34,755.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Natera Inc. (NASDAQ:NTRA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Sramowicz Steven is Buying Rennova Health Inc. (NASDAQ:RNVA) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Rennova Health Inc. (NASDAQ:RNVA) reported that Sramowicz Steven has picked up 3,855,659 of common stock as of 2017-02-01.
The acquisition brings the aggregate amount owned by Sramowicz Steven to a total of 3,855,659 representing a 23.0% stake in the company.
For those not familiar with the company, Rennova Health, Inc. (Rennova), formerly CollabRx, Inc., is a provider of diagnostics and supportive software solutions to healthcare providers. The Company operates in three segments: clinical laboratory operations, supportive software solutions, and decision support and informatics operations. The Company is a healthcare enterprise that delivers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management and intends to provide financial services, to medical providers. Rennova’s principal line of business is clinical laboratory blood and urine testing services. It is also engaged in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Its clinical laboratories include Biohealth Medical Laboratory, Inc.; Alethea Laboratories, Inc.; International Technologies, LLC; EPIC Reference Labs, Inc., and Epinex Diagnostics Laboratories, Inc.
A glance at Rennova Health Inc. (NASDAQ:RNVA)’s key stats reveals a current market capitalization of 4.86 million based on 84.01 million shares outstanding and a price at last close of $0.070 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-07-14, Diamantis picked up 333,333 at a purchase price of $0.44. This brings their total holding to 681,526 as of the date of the filing.
On the sell side, the most recent transaction saw Alcatel-Lucent unload 7,843 shares at a sale price of $4.60. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Rennova Health Inc. (NASDAQ:RNVA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Picked Up Perrigo Co Plc. (NYSE:PRGO) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Perrigo Co Plc. (NYSE:PRGO) reported that Starboard Value LP. has picked up 9,641,425 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Starboard Value LP. to a total of 9,641,425 representing a 6.7% stake in the company.
For those not familiar with the company, Perrigo Company plc is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API), as well as receives royalties from Multiple Sclerosis drug Tysabri®. The company is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market and an industry leader in pharmaceutical technologies.
A glance at Perrigo Co Plc. (NYSE:PRGO)’s key stats reveals a current market capitalization of 11.19 billion based on 143.37 million shares outstanding and a price at last close of $77.76 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-11-21, Parker picked up 2,500 at a purchase price of $88.75. This brings their total holding to 2,500 as of the date of the filing.
On the sell side, the most recent transaction saw Brown unload 2,097 shares at a sale price of $89.44. This brings their total holding to 10,007.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Perrigo Co Plc. (NYSE:PRGO) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Salon Media Group, Inc. (OTCMKTS:SLNM) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported that Spear Point Capital Management Llc. has picked up 190,154,289 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Spear Point Capital Management Llc. to a total of 190,154,289 representing a 69.05% stake in the company.
For those not familiar with the company, Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized and Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company’s primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company’s CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties.
A glance at Salon Media Group, Inc. (OTCMKTS:SLNM)’s key stats reveals a current market capitalization of 5.72 million based on 76.27 million shares outstanding and a price at last close of $0.100 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-06-04, Hambrecht picked up 10,261,429 at a purchase price of $0.35. This brings their total holding to 27,174,322 as of the date of the filing.
On the sell side, the most recent transaction saw Warnock unload 10,261,429 shares at a sale price of $0.35. This brings their total holding to 34,878,281.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Salon Media Group, Inc. (OTCMKTS:SLNM) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Svlsf V, Llc. is Buying Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported that Svlsf V, Llc. has picked up 2,857,667 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Svlsf V, Llc. to a total of 2,857,667 representing a 15.3% stake in the company.
For those not familiar with the company, Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company’s primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company’s CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties.
A glance at Catabasis Pharmaceuticals Inc. (NASDAQ:CATB)’s key stats reveals a current market capitalization of 23.71 million based on 18.65 million shares outstanding and a price at last close of $1.23 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-06-30, George picked up 12,422 at a purchase price of $12.00. This brings their total holding to 90,764 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Just Picked Up Ocular Therapeutix Inc. (NASDAQ:OCUL) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ocular Therapeutix Inc. (NASDAQ:OCUL) reported that Svlsf V, Llc. has picked up 1,605,207 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Svlsf V, Llc. to a total of 1,605,207 representing a 6.5% stake in the company.
For those not familiar with the company, Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP. The OTX-DP product candidate incorporates the corticosteroid dexamethasone as an active pharmaceutical ingredient in its punctum plug.
A glance at Ocular Therapeutix Inc. (NASDAQ:OCUL)’s key stats reveals a current market capitalization of 198.42 million based on 28.76 million shares outstanding and a price at last close of $6.89 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-15, Sawhney picked up 45,300 at a purchase price of $7.85. This brings their total holding to 677,390 as of the date of the filing.
On the sell side, the most recent transaction saw Fortune unload 9,470 shares at a sale price of $17.16. This brings their total holding to 112,060.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ocular Therapeutix Inc. (NASDAQ:OCUL) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) reported that Svlsf V, Llc. has picked up 2,579,490 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Svlsf V, Llc. to a total of 2,579,490 representing a 26.6% stake in the company.
For those not familiar with the company, KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
A glance at Kalvista Pharmaceuticals Inc. (NASDAQ:KALV)’s key stats reveals a current market capitalization of 70.68 million based on 9.93 million shares outstanding and a price at last close of $7.16 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-04-14, Cha picked up 7,364 at a purchase price of $5.00. This brings their total holding to 4,204,562 as of the date of the filing.
On the sell side, the most recent transaction saw Renzi unload 10,000 shares at a sale price of $3.70. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.